Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine ( @ g/day ) for @ weeks ; @ participants were then randomly assigned ( @:@ ) to a group that continued its current dose of mesalamine ( controls , n = @ ) or a group that increased its dose by @ g/day for @ weeks ( n = @ ) .